muramylnac-ala-isogln-lys-tripeptide has been researched along with g(m1) ganglioside in 1 studies
| Studies (muramylnac-ala-isogln-lys-tripeptide) | Trials (muramylnac-ala-isogln-lys-tripeptide) | Recent Studies (post-2010) (muramylnac-ala-isogln-lys-tripeptide) | Studies (g(m1) ganglioside) | Trials (g(m1) ganglioside) | Recent Studies (post-2010) (g(m1) ganglioside) |
|---|---|---|---|---|---|
| 50 | 4 | 1 | 4,120 | 73 | 677 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deodhar, S; Gautam, S | 1 |
1 other study(ies) available for muramylnac-ala-isogln-lys-tripeptide and g(m1) ganglioside
| Article | Year |
|---|---|
Generation of tumoricidal effector cells by human C-reactive protein and muramyl tripeptide: a comparative study.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; C-Reactive Protein; Complement System Proteins; Cytotoxicity, Immunologic; Drug Carriers; G(M1) Ganglioside; Glycosphingolipids; Immune Sera; Immunoglobulins; Isoantibodies; Liposomes; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Neutralization Tests | 1989 |